SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs upcoming Phase 3 REGAL trial results for its GPS leukemia treatment dominate discussion, with topline data expected this month after the trial reached its final analysis milestone. Traders are split between optimism about a potential breakthrough and concern over the binary trial outcome, while sharp price swings have fueled debate about selling pressure and alleged short-term manipulation.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summits FDA review of ivonescimab for EGFR-mutated lung cancer is driving a binary-outcome debate over approval versus a possible rejection or request for more evidence. Bulls point to strong progression-free-survival results and encouraging survival trends, while bears focus on the FDAs stated need for statistically significant overall-survival evidence; recent weakness has also prompted speculation about a negative outcome, though traders say price action alone is not proof.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unitys strong Q3 resultsits first GAAP-profitable quarter, rapid growth in its Vector ad platform, and upbeat outlookhave fueled a sharp rebound and discussion of a possible turnaround. Reported takeover talks with Silver Lake and Saudi Arabias PIF add speculation, with traders debating whether the discussed valuation would undervalue the company or whether a deal will happen at all.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian shares are under pressure amid a broader pullback in EV and growth stocks, with traders also focused on the stocks persistent weakness and concerns about cash burn, profitability, and management. Some blame short sellers or trading dynamics, while bulls point to R2 progress and recent operating results as reasons for optimism; those explanations remain debated.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is selling off after lowering its revenue outlook amid delays activating third-party data-center capacity, prompting analyst concerns about execution and near-term growth; weakness across AI and neocloud stocks, alongside uncertainty around Nvidia, is adding pressure. Traders are split between viewing the delays and higher spending as serious risks and seeing them as temporary setbacks in a business with strong AI demand.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

American Airlines is drawing attention over the squeeze from elevated jet-fuel costs, linked by traders to oil-market disruption and the Iran conflict, with recent earnings discussion highlighting that strong revenue has not translated into profits and the outlook has weakened. Bears worry about prolonged fuel pressure and AALs debt, while bulls see room for recovery if oil prices ease and travel demand remains firm.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs abrupt departure and the unresolved CEO succession are driving concern, with traders divided between those calling for his return and those worried about leadership continuity and scrutiny of Nvidias China-related chip sales. Upcoming earnings are another focus, but bullish bets on results and dip-buying compete with fears that uncertainty and further fallout could weigh on the stock.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novos quarterly results beat expectations and its full-year outlook was raised, with strong demand for the Wegovy pill driving the improved outlook. Traders welcomed the evidence of a growth recovery but remain divided over whether oral Wegovy can offset diabetes weakness and competitive and pricing pressure from Lilly.

HawKeye 360, Inc. engages in the provision of defense technology. It offers spectrum monitoring, maritime intelligence, air defence radar monitoring, GNSS interference detection, and communications mapping. Its costumers include a wide range of commercial, government and international entities. The company was founded by Charles T. Clancy, Robert G. McGwier, Chris DeMay and John Serafini in 2015 and is headquartered in Herndon, VA.

HawkEye 360 Inc.

HAWK is drawing attention after reporting record third-quarter revenue and raising its full-year outlook, with traders also highlighting international growth, contract demand, and plans for lower-cost satellites. The community reaction is broadly bullish on the results and rally, though claims of institutional accumulation and further upside remain speculative.

Newsmax Inc. is a holding company, which engages in television broadcasting and multi-platform content publishing that produces original news and editorial content for consumers through various media outlets, including TV new channels, digital and print publications. It operates through the Broadcasting and Digital Segments. The Broadcasting segment produces and licenses news, business news and lifestyle content for distribution through both MVPDs and free OTT streaming platforms. The Digital segment is composed of Newsmax.com and affiliated websites. The company was founded by Christopher Ruddy in 1998 and is headquartered in Boca Raton, FL.

Newsmax Inc. - Ordinary Shares - Class B

Newsmax Inc

Newsmaxs stronger-than-expected Q3 results and upbeat outlook are driving attention, with traders highlighting improved profitability and revenue growth. Bullish reactions include short-squeeze speculation, while some question how much of the reported strength is recurring because results included a one-time payment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

YD Bio (NASDAQ:YDES) Shares Up 2.8% - Here's Why

YD Bio (NASDAQ:YDES) Shares Up 2.8% - Should You Buy...

YD Bio (NASDAQ:YDES) Shares Gap Up - What's Next?

YD Bio (NASDAQ:YDES) Shares Gap Up - Here's What Happened...

YD Bio (NASDAQ:YDES) Trading Down 3.5% - Here's What Happened

YD Bio (NASDAQ:YDES) Trading Down 3.5% - Time to Sell...

YD Bio (NASDAQ:YDES) Trading 12.5% Higher - Here's Why

YD Bio (NASDAQ:YDES) Trading 12.5% Higher - Here's Why...

Apogee Therapeutics, Tower Semiconductor, Norwegian Cruise Line And Other Big Stocks Moving Higher On Thursday

Stocks fall, Nasdaq drops 200 points. Apogee Therapeutics (APGE) rises 19.4% on positive trial data. Satellogic (SATL), YD Bio (YDES), AXT Inc (AXTI) also see gains.read more...

YD Bio (NASDAQ:YDES) Sets New 52-Week Low - Here's What Happened

YD Bio (NASDAQ:YDES) Hits New 52-Week Low - Should You Sell...

YD Bio (NASDAQ:YDES) Stock Price Down 5.6% - Here's Why

YD Bio (NASDAQ:YDES) Trading Down 5.6% - Here's Why...

YD Bio (NASDAQ:YDES) Trading 7.9% Higher - Still a Buy?

YD Bio (NASDAQ:YDES) Stock Price Up 7.9% - What's Next...

YD Bio (NASDAQ:YDES) Shares Gap Up - Time to Buy?

YD Bio (NASDAQ:YDES) Shares Gap Up - Time to Buy...

YD Bio (NASDAQ:YDES) Stock Price Down 9.1% - Here's Why

YD Bio (NASDAQ:YDES) Stock Price Down 9.1% - Here's What Happened...

YD Bio Ltd. is a biotechnology company building an integrated healthcare platform across regulated diagnostics, clinical services, and commercial healthcare markets. It operates DNA methylation–based oncology testing programs under an LDT-first strategy and provides compliant life science distribution and clinical trial supply chain services to pharmaceutical and biotechnology partners. The company’s offerings include cancer detection products, regenerative ophthalmology solutions, and exosome-based technologies. YD Bio was founded on February 6, 2024 and is headquartered in Taipei, Taiwan.

YD Bio Ltd.

YD Bio Stock Rises On Entry Into US Eye Care Segment

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>The company also said that its Exovisse Artificial Tears have been developed in compliance with FDA mandates permitting nationwide over‑the‑counter distribution.</li><li>YD Bio now plans to conduct a small clinical trial in Taiwan to evaluate dry eye disease in collaboration with 3D Global Biotech.</li><li>The company is also advancing LSC Exosome Therapeutics through its collaboration with 3D Global Biotech for retinal and macular disorders.</li></ul>Taiwan-based biotechnology company YD Bio (YDES) said on Monday that it has reached a set of milestones that together mark its commercial entry into U.S. eye care.Following the announcement, shares of the firm traded 7% higher at the time of writing. &nbsp;The Taiwan-based company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ydesgroup.com/pressreleases/detail/23e04a99-0c62-4d1e-bd0e-ea782181d34c">said</a> that Exovisse Contact Lenses have obtained U.S. Food and Drug Administration clearance through its partner, 3D Global Biotech, confirming that the lenses are substantially equivalent to an already marketed device and can be sold in the U.S.The company also said that its Exovisse Artificial Tears have been developed in compliance with FDA mandates permitting nationwide over‑the‑counter distribution for eye hydration and dry eye comfort without individual FDA premarket approval.<h2 class="st-heading-2">Future Plans</h2>YD Bio now plans to conduct a small clinical trial in Taiwan to evaluate dry eye disease in collaboration with 3D Global Biotech and Taiwan-based contract research organization YC Biotech.The company is also advancing LSC Exosome Therapeutics through its collaboration with 3D Global Biotech for retinal and macular disorders. LSC exosome therapeutics refers to the use of exosomes derived from limbal stem cells (LSCs) for therapeutic purposes, particularly for conditions affecting the eye, like dry eye syndrome.The company said that it has enrolled its limbal stem cells and limbal stem cell exosomes in the FDA Drug Master File, establishing documentation to support future therapeutic development.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around YDES stayed within the ‘neutral’ territory while message volume remained at ‘extremely low’ levels.<figure class="image"><img style="aspect-ratio:586/61;" src="data:image/png;base64,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" width="586" height="61" alt="YDES’s Sentiment Meter and Message Volume as of 12:37 p.m. ET on Nov. 24, 2025 | Source: Stocktwits"><figcaption>YDES’s Sentiment Meter and Message Volume as of 12:37 p.m. ET on Nov. 24, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/YDES">YDES stock</a> is down by 20% this year and by about 22% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pharma-bro-martin-shkreli-goes-short-on-capircor-therapeutics/cL5bQHUREQS">‘Pharma Bro’ Martin Shkreli Goes Short On Capricor Therapeutics – Stock Tumbles 17%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

The Taiwan-based company said that Exovisse Contact Lenses have obtained the U.S. Food and Drug Administration’s clearance through its partner 3D Global Biotech.

Fidelity Nasdaq Composite Index ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

YDES News